NFKB1 and diffuse large B-cell lymphoma: Most probably, miR-181a/b regulates genes related to the NF-κB and p38/MAPK pathways because aberrant activation and high expression of the proteins related to these two pathways are closely associated with cell survival and resistance of DLBCL cells to immunochemotherapy; their inhibition significantly increases the therapeutic effects of immune chemotherapy [20–22].